KDIGO guideline (2024): evaluation and management of chronic kidney disease MCQ (SBA): CKD G3b A3
Instant feedback + full explanation. One question, done properly.
MediumKDIGO and ADA/KDIGO consensus recommend ns‑MRA (e.g. finerenone) for persistent albuminuria despite ACEi/ARB and SGLT2 inhibitorCKD G3b A3KDIGO guideline (2024): evaluation and management of chronic kidney disease
Educational content. Not a substitute for clinical judgement or local policy.